Side-by-side comparison of AI visibility scores, market position, and capabilities
Absci is an AI drug creation company that combines generative AI with a synthetic biology platform to design novel therapeutic proteins from the ground up.
Absci is a publicly traded AI drug creation company founded in 2011 that went public in 2021 and has repositioned around generative AI for drug design. The company operates an integrated platform that uses generative AI to design novel antibodies and proteins, then validates them using high-throughput expression and biological assay systems in its own wet lab infrastructure. Absci's approach treats drug discovery as a generative design problem, using AI to propose protein sequences with desired therapeutic properties and then rapidly testing millions of candidates to identify viable drug leads. The company has established drug creation partnerships with major pharmaceutical companies including AstraZeneca, Merck, and EQT Life Sciences. Absci's technical differentiation lies in its ability to close the loop between AI-generated protein designs and experimental validation at unprecedented scale. The company represents a new category of AI-native biopharmaceutical company that combines computational and wet-lab capabilities to create drugs not discoverable through traditional means.
CrowdStrike (CRWD) reported $3.95B ARR in FY2025 (ended Jan). Revenue $3.74B, up 29% YoY. Market cap ~$85B. 8,600+ employees. Austin, TX. AI-native cybersecurity platform. Charlotte AI for threat detection.
CrowdStrike is an AI-native cybersecurity company founded in 2011 by George Kurtz, Dmitri Alperovitch, and Gregg Marston and headquartered in Austin, Texas, that built the endpoint detection and response (EDR) category and has since expanded into the broadest cloud-native cybersecurity platform in the industry. The company was founded on the insight that traditional antivirus software — signature-based, retrospective, and endpoint-isolated — could not keep pace with sophisticated adversaries operating at machine speed. CrowdStrike's founding architecture, the Falcon platform, was designed cloud-native from day one: a single lightweight agent on the endpoint feeding a cloud-based AI that learns from trillions of security events across every customer simultaneously. The company trades on Nasdaq under the ticker CRWD.\n\nThe CrowdStrike Falcon platform consolidates more than 28 security modules across endpoint security, identity threat protection, cloud security, next-gen SIEM and log management, threat intelligence, and managed detection and response — all delivered through a single agent and unified console. The AI at the platform's core, Charlotte AI, provides conversational security operations, automated investigation, and AI-generated threat summaries that reduce analyst workload. CrowdStrike's threat intelligence team, Adversary Intelligence, tracks and names nation-state and criminal threat actors globally, giving customers predictive insight into campaigns before they hit their environments.\n\nCrowdStrike reported $3.95 billion in annual recurring revenue (ARR) for FY2025 and total revenue of $3.74 billion, up 29% year over year, with a market capitalization of approximately $85 billion. The company has 8,600+ employees and counts a substantial share of the Fortune 500 and global governments as customers. Despite the July 2024 sensor update incident that caused a significant IT outage affecting millions of Windows systems globally, CrowdStrike's customer retention remained strong — a testament to the platform's depth of integration and the switching costs built into its consolidated architecture.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.